Home » Newsletters » BioWorld Science

BioWorld Science

April 7, 2020

View Archived Issues

Smart bacterium senses environment

The dose makes the poison -- timing, too

Head and neck cancer cachexia mouse model developed

Large-scale proteomic analysis unveils a shift in glutaminate fate involved in cancer progression

GRASP55 plays a key physiological role in intestinal lipid uptake

Ennaid begins development of ENU-200 for COVID-19 infection

Glycoprotein negatively regulates adult neurogenesis

First patient dosed in phase I study of COM-902 in advanced malignancies

Opaganib approved for compassionate use in patients with COVID-19 in Italy

Millendo Therapeutics discontinues development of livoletide for PWS

European Commission approves Nilemdo and Nustendi

AXS-07 achieves both coprimary endpoints in INTERCEPT phase III study

Mesoblast's IND for remestemcel-L in COVID-19-related ARDS receives clearance

IRF-1 as a novel therapeutic target in CKD

Novel alpha-ketoamide inhibitor with activity against main protease of SARS-CoV-2

Ono Pharmaceutical divulges PTGDR2 antagonists

Chinese researchers patent compounds for cancer

Bristol-Myers Squibb synthesizes new LPA1 receptor antagonists

Hanmi Science presents new EGFR mutant inhibitors

Pfizer discloses new CCR6 antagonists

FDA accepts IND for phase I testing of INO-4800 for COVID-19

FDA clears IND application for EIDD-2801 for COVID-19

SARS-CoV-2 vaccine shows promise in first peer-reviewed article on a potential COVID-19 vaccine

PKX-001 demonstrates safety and efficacy in dry eye disease model

Crinetics reports interim data from phase II ACROBAT EDGE trial of paltusotine in acromegaly

Aviptadil enters clinical trials to treat COVID-19-related ARDS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...